The pharmaceutical industry continues to search for a variety of new cures for many conditions. One of the entities around which researchers' interests are focused is atopic dermatitis (AD). It is possible that a new drug for this dermatological condition will soon be more widely available on the medical market - dupilumab could be it. This product is an antibody that inhibits the inflammatory response in the body and was approved in early 2017 for the treatment of atopic dermatitis.